Is it necessary to conduct trials with trimethoprim-sulphamethoxazole amongst HIV-infected individuals in Africa? [7]

AIDS

Volumn 12, Issue 4, 1998, Pages 447-

  Samb, B ^a   Badiane, M ^a   Kony, S ^a   Larouze, B ^a   Faye, M A ^a   Sow, P S ^a   Badiane, S ^a   Metro, A ^a   Costagliola, D ^a   Ndoye, I ^a   Delaporte, E ^a   Coll Seck, A M ^a   Coulaud, J P ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

AFRICA; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LETTER; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXOPLASMOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; DOUBLE-BLIND METHOD; HUMANS; PNEUMONIA, PNEUMOCYSTIS; SENEGAL; TOXOPLASMOSIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0032485233     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)